Medtronic announced it has entered into a definitive agreement to acquire Scientia Vascular for $550 million, with additional potential earn-out and milestone payments. The transaction is expected to strengthen Medtronic’s neurovascular portfolio by combining its therapeutic technologies with Scientia’s specialized access devices used in complex neurovascular procedures.
Scientia Vascular is a privately held company based in Salt Lake City, Utah, employing approximately 310 people. Founded by John Lippert, the company develops guidewires and catheter-based technologies designed to help physicians navigate the intricate structure of cerebral blood vessels during procedures for conditions such as stroke and aneurysms.
Medtronic said the integration of Scientia’s access products with its existing neurovascular therapies will enhance the company’s ability to support physicians throughout the full procedural workflow. The combined portfolio aims to improve navigability in complex anatomy and streamline procedures, helping clinicians reach the treatment site faster.
The announcement highlights the urgency of innovation in stroke treatment, noting that stroke remains the third leading cause of death and a leading cause of disability worldwide, affecting approximately 12 million people annually. Because brain tissue deteriorates rapidly when blood flow is blocked, faster access to the treatment site can significantly influence outcomes.
Scientia’s platform focuses on improving access through the highly tortuous cerebral vasculature. These technologies are designed to help physicians navigate difficult pathways more reliably, potentially enabling faster therapy delivery and improved procedural efficiency.
Medtronic stated that the acquisition will support procedures addressing both hemorrhagic stroke and acute ischemic stroke. By combining its established therapeutic devices with Scientia’s access technologies, the company aims to create a more comprehensive neurovascular toolkit for physicians.
The transaction is expected to close in the first half of Medtronic’s fiscal year 2027, subject to regulatory approvals and other customary closing conditions. Medtronic said the deal is expected to be minimally dilutive to adjusted earnings per share in fiscal year 2027 and accretive thereafter.
Scientia’s leadership indicated that joining Medtronic will allow the company’s engineering innovations to scale globally and reach more patients through Medtronic’s established distribution and clinical network.
KEY QUOTES:
“Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care. This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic’s best-in-class therapies, combined with Scientia’s leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world.”
Linnea Burman, Senior Vice President And President Of Medtronic’s Neurovascular Business
“As a company committed to improving patients’ lives, we are humbled and excited for what’s ahead. Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting.”
Rick Randall, CEO Of Scientia
“Microwires and microcatheters are required for all neurointerventional cases. Correspondingly, better microwires and microcatheters make every single case technically easier, faster and ultimately safer for patients. This revolutionary microwire technology has enabled – and will continue to enable – access and simplify the neurovascular procedures we do.”
Dr. David Fiorella, Director Of The Cerebrovascular Center At Stony Brook Medicine
